



Sequella, Inc.  
9610 Medical Center Drive  
Rockville, MD 20850  
Tele: 301-762-7776  
[www.sequella.com](http://www.sequella.com)

## NEWS RELEASE

March 5, 2007

### Sequella to Present at BIO-Europe Spring 2007

ROCKVILLE, Md -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential, was selected to present a company overview on Tuesday, March 6, 2007 at BIO-Europe in Milan, Italy. Mr. Alan Klein, Sequella's Executive Vice President for Corporate Development will make a presentation outlining licensing opportunities, key technologies, product and clinical development activities, and existing alliances.

"Because of its track record in product development, Sequella was selected to present from amongst several hundred applicants," said Mr. Klein. Sequella recently received Fast Track designation from the U. S. Food and Drug Administration (FDA) for SQ109, the company's proprietary lead drug candidate. SQ 109 has a mechanism of action distinct from other antibiotics used in TB therapy, and shows excellent *in vitro* activity against drug susceptible and drug resistant TB bacteria, including XDR-TB, as well as potent *in vivo* activity against pulmonary TB alone and with other TB drugs. The company has also developed the TB Patch, a new diagnostic that has shown in clinical trials to more quickly and accurately detect active TB in patients, and also received a US patent for the first in a series of applications covering methods and compositions of Translocase I inhibitor drug compounds.

"We believe that if our therapies are commercialized, they may set a new gold standard in the treatment of this life-threatening and potentially epidemic infectious diseases," said Mr. Klein.

Sequella officials will also be present at BIOSquare (Business Partnering) in Lyon, France March 11-14, 2007.

#### About Sequella, Inc.

Sequella is a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential. The company leverages its global influence, infectious disease expertise, and diverse product portfolio to proactively address emerging health threats with significant market opportunity. The Company's lead drug candidate, SQ109, a new orally-active diamine antibiotic for the treatment of tuberculosis (TB) and other infectious diseases, is presently in Phase I clinical studies and has received the FDA Fast Track designation. The company's lead diagnostic product candidate, the TB Patch, is completing several international clinical trials in anticipation of world-wide product registration. For more information, please visit [www.sequella.com](http://www.sequella.com).

#### Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.